Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition.


Purpose: Adenoid cystic carcinoma (ACC) is a rare cancer arising from the major or minor salivary gland tissues of the head and neck. There are currently no approved systemic agents or known radiosensitizers for ACC. Unlike the more common head and neck squamous cell carcinomas that frequently harbor TP53 mutations, ACCs contain TP53 mutations at a rate of… (More)
DOI: 10.1158/1078-0432.CCR-17-0969


Cite this paper

@article{Prabakaran2017RadiosensitizationOA, title={Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition.}, author={Prashanth J Prabakaran and Amal M Javaid and Adam D Swick and Lauryn R Werner and K Nickel and Emmanuel Sampene and Rong Hu and Irene M. Ong and Justine Yang Bruce and Gregory K. Hartig and Aaron M. Wieland and Jude Canon and Paul M. Harari and Randall J. Kimple}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2017}, volume={23 20}, pages={6044-6053} }